▶주메뉴 바로가기
▶본문 바로가기
South Korean biopharmaceutical company Celltrion said Friday it achieved record revenue in the third quarter, driven largely by increased global prescriptions of its flagship biosimilar products. According to a regulatory filing, Celltrion posted consolidated sales of 881.9 billion won ($645.7 mil...
South Korean stem cell research company Miracell showcased its stem cell extraction system, Smart M-Cell, during the IV Congreso Semdor Valencia conference in Spain last month. Hosted by the Spanish Pain Society, the annual conference brought together pain management experts from around the world ...
Celltrion has launched Steqeyma, a biosimilar of Stelara (ustekinumab) for autoimmune disease treatment, across Europe, broadening its product portfolio to further strengthen its position in the European biopharmaceutical market. On Friday, Celltrion introduced Steqeyma in Germany, one of Europe’...
Celltrion has secured contracts to list its Zymfentra — the world’s only subcutaneous injection formulation of its infliximab Remsima — across all public and private insurance sectors managed by the top three US pharmacy benefit managers. Celltrion announced Tuesday that it had recently finaliz...
South Korean pharmaceutical company SK Bioscience said Wednesday that its SKYCellflu has become the first influenza vaccine from Korea approved by the Food and Drug Agency of Indonesia. Indonesia’s pharmaceutical market has been growing significantly. According to market tracker Insights10, the c...
LG Chem said Thursday that it plans to commercialize an eco-friendly ingredient derived from plant-based oils for cosmetic products, becoming the first to do so. The South Korean chemicals giant is set to develop functional cosmetics using 100 percent bio-based 3-hydroxypropionic acid, a compound ...
Samsung Biologics announced Monday that it has launched S-HiCon, a new platform specializing in high-concentration formulation development, designed to meet rising demand for high-concentration biopharmaceuticals. The company officially introduced the platform at Bio Japan 2024, a biotechnology ex...
South Korean biotech firm SK Bioscience said Tuesday it has invested $3 million in the US-based biotech firm Fina Biosolutions to acquire a stake in the company as part of the company’s broader strategy to secure next-generation vaccine technologies and enhance its global competitiveness in the va...
SK Innovation, with its subsidiary SK IE Technology and researchers from Yonsei University, has developed a next-generation technology designed to capture carbon emissions more efficiently and at a lower cost. This breakthrough could have significant implications for the biggest carbon-emitting ind...
South Korean drug maker Daewoong Pharmaceutical said Monday that more than 88 percent of its patents registered over the past five years in the country have been for new drugs, reflecting the firm’s efforts to enhance its competitiveness in both domestic and global markets through the development ...
South Korean pharmaceutical giant Yuhan announced Friday it has terminated its collaboration with Janssen Biotech on the development of a next-generation targeted anticancer drug, citing the strong efficacy of its existing treatment, which has reduced the need for further development. According to...
According to the group, most raw materials for hyperlipidemia drugs produced in Korea are currently manufactured using a "batch process" method, which operates each process separately. In contrast, Daewoong's "continuous process" ensures consistent quality by allowing raw materials to be input in a...
South Korean biosimilar giant Celltrion will continue to supply trastuzumab biosimilar Herzuma to Brazil, the company announced Friday. The company won the bid to supply a trastuzumab biosimilar to the Brazilian Federal Government for the fifth consecutive year. Under the contract, Celltrion will...
Celltrion’s Remsima SC, the world’s only subcutaneous formulation of infliximab, has reached a record market share in Australia, the Korean biosimilar giant announced Wednesday. According to data from pharmaceutical market research firm IQVIA, Remsima SC achieved a 20 percent market share for th...
South Korean biosimilar giant Celltrion announced Wednesday that Steqeyma, the company's biosimilar referencing Stelara, has been approved in the UK, following earlier approvals by Korea, Canada and the European Commission this year. According to the company, Steqeyma has received approval from th...
[Contribution] Investment diary of a CIO’s son
[KH Explains] For Korean automakers, Chinese EVs may loom larger than Tump’s tariffs
Renault Grand Koleos boasts 30% share in hybrid SUVs
Korea Zinc pulls back on capital increase scheme
Solidigm launches industry's largest capacity eSSD for AI data centers
Samsung stocks fall to 4-year low